Insider · CIK 0001707797
Rita Jain
director
Files at CLDX (Celldex Therapeutics, Inc.), ANAB (ANAPTYSBIO, INC), AVTX (Avalo Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +1,322 | $12.29 | $16k | 1,322 | 10 d ago |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,200 | $0.00 | $0 | 40,200 | Jun 18, 2025 |
| Jun 15, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Common Stock | +7,330 | $0.00 | $0 | 11,864 | Jun 17, 2025 |
| Jun 15, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -1,300 | $0.00 | $0 | 1,300 | Jun 17, 2025 |
| Jun 15, 2025 | ANAB ANAPTYSBIO, INC | MOption exercise Restricted Stock Unitderivative | -6,030 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Stock Option (right to buy)derivative | +16,510 | $0.00 | $0 | 16,510 | Jan 7, 2025 |
| Jan 7, 2025 | ANAB ANAPTYSBIO, INC | AGrant or award Restricted Stock Unitderivative | +6,030 | $0.00 | $0 | 6,030 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.